pharmaceutics

IMPACT FACTOR 5.4

Indexed in: PubMed

CITESCORE 6.9

an Open Access Journal by MDPI

Bioavailability and Bioequivalence of Locally Acting Colon-Targeted Products: In Vivo and In Vitro Considerations

Guest Editors:

Prof. Dr. Abdul W. Basit
Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK

Dr. Jozef Al-Gousous
1. Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, D-55099 Mainz, Germany
2. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA

Deadline for manuscript submissions:
closed (15 October 2021)

Message from the Guest Editors

Dear Colleagues,

Targeting drug release to the colon has been a major research topic over the past three decades. Potential applications for colon-targeted products include localized therapy of colonic pathologies (e.g., inflammatory bowel disease and colon cancer). Multiple approaches to colonic delivery exist, such as pH-dependent, microbe-dependent, time-dependent and pressure-dependent drug delivery systems. One of the aspects that sets localized drug delivery apart from systemic drug delivery is the fact that the site of action is located before systemic circulation, making the value of traditional bioavailability and bioequivalence studies questionable. This is sometimes compounded by the poor colonic permeability of many drug substances, resulting in drug release and availability at the site of action being poorly reflected by the drug plasma concentration profile (if observable), which is then shaped by the strong rate-limiting permeation step. Therefore, research into alternative in vivo approaches as well as into in vitro testing methods that exhibit satisfactory in vivo predictivity (preferably without entailing high complexity) is often needed.

pharmaceutics

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 6.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
𝕏@MDPIpharma